Swiss National Bank Has $3.38 Million Position in Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI)

Swiss National Bank lowered its stake in shares of Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVIFree Report) by 10.6% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 241,300 shares of the company’s stock after selling 28,700 shares during the quarter. Swiss National Bank owned about 0.09% of Maravai LifeSciences worth $3,381,000 at the end of the most recent reporting period.

Other large investors have also added to or reduced their stakes in the company. Zions Bancorporation N.A. acquired a new stake in Maravai LifeSciences during the first quarter worth approximately $28,000. Lazard Asset Management LLC grew its position in Maravai LifeSciences by 8,207.5% during the fourth quarter. Lazard Asset Management LLC now owns 3,323 shares of the company’s stock worth $47,000 after buying an additional 3,283 shares in the last quarter. Point72 Hong Kong Ltd acquired a new stake in shares of Maravai LifeSciences in the 1st quarter valued at $163,000. Signaturefd LLC boosted its holdings in shares of Maravai LifeSciences by 144.5% in the 1st quarter. Signaturefd LLC now owns 4,797 shares of the company’s stock valued at $67,000 after purchasing an additional 2,835 shares in the last quarter. Finally, Tower Research Capital LLC TRC boosted its holdings in shares of Maravai LifeSciences by 134.0% in the 1st quarter. Tower Research Capital LLC TRC now owns 4,999 shares of the company’s stock valued at $70,000 after purchasing an additional 2,863 shares in the last quarter. Institutional investors and hedge funds own 50.25% of the company’s stock.

Maravai LifeSciences Stock Down 0.4 %

Shares of NASDAQ:MRVI opened at $10.30 on Friday. The business has a fifty day simple moving average of $11.50 and a 200 day simple moving average of $13.09. Maravai LifeSciences Holdings, Inc. has a 12-month low of $9.20 and a 12-month high of $26.55. The company has a quick ratio of 8.70, a current ratio of 9.33 and a debt-to-equity ratio of 0.62. The firm has a market cap of $2.59 billion, a P/E ratio of 18.07 and a beta of -0.26.

Maravai LifeSciences (NASDAQ:MRVIGet Free Report) last posted its quarterly earnings data on Monday, August 7th. The company reported ($0.06) earnings per share for the quarter, missing the consensus estimate of ($0.02) by ($0.04). Maravai LifeSciences had a return on equity of 20.67% and a net margin of 13.88%. The business had revenue of $68.91 million during the quarter, compared to the consensus estimate of $70.30 million. Analysts predict that Maravai LifeSciences Holdings, Inc. will post -0.06 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on MRVI. Bank of America reduced their target price on Maravai LifeSciences from $15.00 to $12.00 in a report on Tuesday, August 8th. The Goldman Sachs Group dropped their price target on Maravai LifeSciences from $12.00 to $8.00 and set a “neutral” rating for the company in a research note on Tuesday, August 8th. KeyCorp cut Maravai LifeSciences from an “overweight” rating to a “sector weight” rating in a research note on Tuesday, August 8th. Royal Bank of Canada dropped their price target on Maravai LifeSciences from $20.00 to $18.00 and set an “outperform” rating for the company in a research note on Tuesday, August 8th. Finally, Robert W. Baird dropped their price target on Maravai LifeSciences from $18.00 to $11.00 and set an “outperform” rating for the company in a research note on Tuesday, August 8th. Five analysts have rated the stock with a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat, Maravai LifeSciences has an average rating of “Hold” and an average target price of $14.10.

Get Our Latest Analysis on Maravai LifeSciences

Maravai LifeSciences Profile

(Free Report)

Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases in the United States and internationally. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.

See Also

Want to see what other hedge funds are holding MRVI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVIFree Report).

Institutional Ownership by Quarter for Maravai LifeSciences (NASDAQ:MRVI)

Receive News & Ratings for Maravai LifeSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Maravai LifeSciences and related companies with MarketBeat.com's FREE daily email newsletter.